Names
Epcoritamab-bysp Epkinly®Indications and usage
Epcoritamab-bysp is indicated for the treatment of
- Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
- Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy
- Follicular Lymphoma
- Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy
Side effects needing medical attention
LBCL: The most common adverse reactions are cytokine release syndrome, fatigue, musculoskeletal pain, injection site reactions, pyrexia, abdominal pain, nausea, and diarrhea. The most common Grade 3 to 4 lab abnormalities are decreased lymphocyte count, decreased neutrophil count, decreased white blood cell count, decreased hemoglobin, and decreased platelets.
FL: The most common adverse reactions are injection site reactions, cytokine release syndrome, COVID-19, fatigue, upper respiratory tract infection, musculoskeletal pain, rash, diarrhea, pyrexia, cough, and headache. The most common Grade 3 to 4 lab abnormalities are decreased lymphocyte count, decreased neutrophil count, decreased white blood cell count, and decreased hemoglobin.